BPA
ASBPW

Beacon Pointe Advisors’s Aspire Biopharma Warrant ASBPW Stock Holding History

Beacon Pointe Advisors’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$332 Hold
20,000
– – ﹤0.01% 1832
2025
Q4 		$330 Buy
+20,000
New +$616 ﹤0.01% 1504

Other funds holding ASBPW

MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 19.06% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Beacon Pointe Advisors's ASBPW Position: Q1 2026 in Review

Beacon Pointe Advisors held its Aspire Biopharma Warrant (ASBPW) position steady in Q1 2026 at 20,000 shares worth $332. The position accounts for ﹤0.01% of the portfolio, ranked #1832.

Beacon Pointe Advisors first reported a position in ASBPW in Q4 2025 and has held it in 2 quarters since. 29 funds tracked by Wall St. Rank hold ASBPW as of Q1 2026.

  • Beacon Pointe Advisors held 20,000 shares of Aspire Biopharma Warrant worth $332 as of Q1 2026.
  • Beacon Pointe Advisors left its Aspire Biopharma Warrant share count unchanged in Q1 2026.
  • Aspire Biopharma Warrant made up ﹤0.01% of Beacon Pointe Advisors's portfolio in Q1 2026, its #1832 holding.
  • Beacon Pointe Advisors first reported a position in Aspire Biopharma Warrant in Q4 2025 and has held it in 2 quarters since.
  • 29 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q1 2026.

Based on Beacon Pointe Advisors's 13F filing for Q1 2026, filed 15 May 2026.